ERBB2 and breast carcinoma: Phase I/II Study of T‐DM1 Alone Versus T‐DM1 and Metronomic Temozolomide in Secondary Prevention of HER2‐Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery